“It’s really important to us, and it’s really important to you all … that you tell the story of 340B,” HRSA Administrator Carole Johnson told entities yesterday at the 340B Coalition summer conference.
Top federal 340B program officials and the head of a 340B hospital group yesterday urged covered entity representatives attending a meeting near Washington, D.C., to focus on documenting and telling their 340B success stories.
340B hospitals treat higher shares of patients who are dually eligible for Medicare and Medicaid, Medicare patients with disabilities, and Medicare patients under 65, a new study found.
A new study, conducted by L&M Policy Research on behalf of 340B Health, finds hospitals participating in the 340B program treat much higher shares of underserved patients than non-340B hospitals and physicians’ offices. The study was released on July
Research commissioned by 340B Health found that 340B DSH hospitals spent more on uncompensated and unreimbursed care during COVID-19's first year than the year before despite worsening operating margins.
340B disproportionate share hospitals provided more uncompensated and unreimbursed care during 2020 despite a decline in operating margins associated with the COVID-19 pandemic, a new hospital-funded study shows.
The paper by Dobson DaVanzo for hospital group 340B Health
PhRMA and Community Oncology Alliance submitted comments to the FTC criticizing 340B contract pharmacies in response to the commission’s call for public input on PBMs’ business practices.
Growth in 340B covered entities’ use of contract pharmacies to dispense 340B drugs, coupled with growth in pharmacy benefit managers’ control over these pharmacies, has given PBMs an outsized, profit-driven role in the 340B program that does not
NACHC urged HHS Secretary Xavier Becerra to hold drug manufacturers accountable for restricting shipments of 340B drugs to contract pharmacies.
The National Association of Community Health Centers (NACHC) strongly urged the U.S. Health and Human Services Secretary Xavier Becerra yesterday “to swiftly impose” fines on drug manufacturers that restrict shipments of 340B-purchased drugs to contract pharmacies and “hold
NACHC's president and CEO told her counterpart at Merck the company's decision to impose conditions on 340B on health centers, but not on other grantee covered entities, "cannot be explained by logic, only greed.”
The National Association of Community Health Centers this week strongly urged drug manufacturer Merck to eliminate “all conditions imposed on health centers to receive 340B price drugs at contract pharmacies.”
NACHC “would love to see” Congress pass legislation by the end of this year protecting health centers from drug manufacturers and PBMs' restrictions on 340B access, NACHC Senior Vice President Joe Dunn said during a news conference yesterday.
The National Association of Community Health Centers “would love to see” Congress pass legislation by the end of this year that stops drug makers from restricting 340B contract pharmacy arrangements and stops pharmacy benefit managers from taking covered entities’ 340B savings,
An infographic NACHC released today in conjunction with a new survey of its members. The health center association wants Congress and the Biden administration to pass laws protecting centers from drug manufacturer and PBM policies that it says threaten centers' financial viability.
The National Association of Community Health Centers urged Congress and the Biden administration this afternoon to force drug companies to ship 340B drugs to contract pharmacies unconditionally and stop pharmacy benefit managers from siphoning off health centers’ 340B